Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset POMC Deficiency Obesity Due to Bi-Allelic Loss-of-Function POMC or PCSK1 Genetic Mutation

NCT02896192 is registered in ClinicalTrials.gov with Rhythm Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02896192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02896192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset POMC Deficiency Obesity Due to Bi-Allelic Loss-of-Function POMC or PCSK1 Genetic Mutation
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 14, 2017
Completion date
May 25, 2020
Enrollment
15 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

pro-opiomelanocortin (pomc) deficiency obesity